Has Carlos Luciano-Roman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,624 in general payments to Carlos Luciano-Roman, MD across 130 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Carlos Luciano-Roman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Carlos Luciano-Roman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Carlos Luciano-Roman, MD

Neurology · San Juan, PRNPI 1699820431

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Sanofi at 51.3% of the total. Reporting peaked in 2019 at $10,190 and has fallen 91.7% since, to $848 in 2025. Among neurology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,624in general payments, 2019–2025

Across 130 payments — averaging $158.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$11K
Akcea Therapeutics, Inc.$6K
Biogen$608
Novartis$586
AstraZeneca$574
Davol Inc.$290
plus $2K from 18 others

$2,250in research payments, 2019–2025

Across 2 payments — averaging $1125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$2K

What the payments were for

Consulting fees$4,80523%
Speaking & faculty fees$11,38155%
Travel & lodging$120%
Food & beverage$4,42621%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	11	$10,585
Akcea Therapeutics, Inc.	7	$6,375
Biogen	32	$608
Novartis	27	$586
AstraZeneca	16	$574
Davol Inc.	2	$290
Argenx US, Inc.	2	$236
UCB, Inc.	4	$212
Catalyst Pharmaceuticals, Inc.	1	$170
EMD Serono, Inc.	2	$155
Genentech USA, Inc.	7	$141
Lifenet Health	1	$125
Eisai Inc.	1	$125
Eli Lilly Export S.A. Puerto Rico Branch	4	$77
AbbVie(2 entities)	3	$76
Tanabe Pharma America, Inc.	1	$73
PTC Therapeutics, Inc.	1	$38
Johnson & Johnson	2	$34
Amgen	1	$31
E.r. Squibb & Sons, L.L.C.	1	$27
Acorda Therapeutics, Inc	1	$24
Acadia Pharmaceuticals Inc	1	$23
CSL Behring	1	$20
Pfizer Pharmaceuticals LLC	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,624 in reported general payments places this provider in the 90th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$7,558

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Pyridostigmine Bromide	52	$3,464
Levocarnitine	14	$2,068
Pregabalin	58	$1,164
Riluzole	18	$1,104
Gabapentin	90	$963
Lacosamide	12	$600
Baclofen	20	$510
Duloxetine Hcl	31	$498
Prednisone	44	$436
Diazepam	23	$363
Donepezil Hcl	21	$115
Tizanidine Hcl	12	$102
Lamotrigine	11	$92

Paid to pharmacies, not to this prescriber.

Other neurology in San Juan

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →